Truist Financial Maintains Lineage(LINE.US) With Buy Rating, Maintains Target Price $94
Truist Financial Maintains Lineage(LINE.US) With Buy Rating, Maintains Target Price $94
Optimistic Growth and Profitability Forecast for Lineage, Inc. Justifies Buy Rating
Lineage Is Maintained at Equal-Weight by Wells Fargo
Evercore Maintains Lineage(LINE.US) With Hold Rating, Raises Target Price to $90
Evercore ISI Adjusts Price Target on Lineage to $90 From $88, Maintains In Line
Wells Fargo Initiates Lineage(LINE.US) With Hold Rating, Announces Target Price $89
Wells Fargo Maintains Lineage(LINE.US) With Hold Rating, Raises Target Price to $89
Lineage Price Target Cut to $94.00/Share From $95.00 by Scotiabank
Lineage Analyst Ratings
Scotiabank Maintains Lineage(LINE.US) With Buy Rating, Maintains Target Price $95
Lineage, Inc. (LINE) Initiated With a Buy at Scotiabank
Analysts Are Bullish on Top Real Estate Stocks: Lineage, Inc. (LINE), K Wah International Holdings (KWHAF)
Evercore Maintains Lineage(LINE.US) With Hold Rating, Maintains Target Price $88
Evercore ISI Keeps Their Hold Rating on Lineage, Inc. (LINE)
Morgan Stanley Maintains Lineage(LINE.US) With Buy Rating, Maintains Target Price $100
Craig-Hallum Initiates Lineage Cell Therapeutics at Buy With $4 Price Target
A Quick Look at Today's Ratings for Lineage(LINE.US), With a Forecast Between $86 to $105
Lineage Cell Therapeutics Price Target Announced at $4.00/Share by Craig-Hallum
Lineage Cell Therapeutics Analyst Ratings
No Data